Clinical trials: Pemphigus Vulgaris (PV)
Pemphigus Vulgaris
A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)
This is a Phase III, randomized, double-blind, double-dummy, active-comparator, parallel-arm, multicenter study to evaluate the efficacy and safety of rituximab compared with MMF in participants with moderate-to-severely active…
- Trial name
- NCT02383589
- Testing
- Mycophenolate Mofetil, Rituximab
- Where
- 68 sites in United States, Argentina and 10 more
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
Pemphigus
A Study of PRN1008 in Patients With Pemphigus
This was a Phase 3 randomized, parallel-group, double-blind, placebo-controlled trial (blinded treatment [BT] period) followed by an open-label extension [OLE] period intended to evaluate the efficacy and safety of oral PRN1008…
- Trial name
- NCT03762265
- Testing
- Rilzabrutinib
- Where
- 88 sites in United States, Argentina and 17 more
- Volunteers
- 131 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Pemphigus Vulgaris (PV)
A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
This study was designed to assess the efficacy and safety of CellCept (1 g or 1.5 g orally twice daily for 52 weeks) in patients with pemphigus vulgaris receiving prednisone or other corticosteroids.
- Trial name
- NCT00683930
- Testing
- Mycophenolate Mofetil 2 g/Day, Mycophenolate Mofetil (MMF) 3 g/Day
- Where
- 26 sites in United States, Canada and 6 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Pemphigus Vulgaris
Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris
Pemphigus vulgaris (PV) is a rare, chronic, debilitating, and potentially life-threatening autoimmune disorder that is characterized by mucocutaneous blisters.
- Trial name
- NCT01920477
- Testing
- Ofatumumab
- Where
- 16 sites in United States, Australia and 6 more
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals